What is claimed is:

1. Use of an interleukin-4 receptor (IL-4R) inhibitor in the manufacture of a medicament for treating or ameliorating at least one symptom or indication of eosinophilic esophagitis (EoE) in a subject having a history of diagnosis of EoE, wherein the subject has ≥ 15 eosinophils per high powered field (hpf) from a esophageal biopsy specimen, wherein the IL-4R inhibitor is an antibody or an antigen binding fragment thereof that specifically binds interleukin-4 receptor alpha (IL-4Rα), wherein the antibody or antigen-binding fragment thereof comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO:3, a HCDR2 comprising the amino acid sequence of SEQ ID NO:4, a HCDR3 comprising the amino acid sequence of SEQ ID NO:5, a LCDR1 comprising the amino acid sequence of SEQ ID NO:6, a LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:8, and wherein the IL-4R inhibitor is formulated to be subcutaneously or intravenously administered to the subject.

2. The use of claim 1, wherein the subject:

(i) has a history of at least 2 episodes of dysphagia;

(ii) is inadequately responsive to treatment with a swallowed topical corticosteroid; and/or

(iii) is inadequately responsive to diet modification.

3. The use of any one of claims 1 – 2, wherein the subject has a concurrent disease or disorder selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis and inherited connective tissue disorders.

4. The use of any one of claims 1 – 3, wherein the subject is an adult.

5. The use of any one of claims 1 – 4, wherein the subject to be treated:

has a serum IgE level of ≥ 150 kU/L; and/or

has a peripheral eosinophil count of ≥ 300 cells/μL.

6. The use of any one of claims 1-5, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) that comprises the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) that comprises the amino acid sequence of SEQ ID NO: 2.

7. The use of any one of claims 1-6, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 13 and a light chain comprising the amino acid sequence of SEQ ID NO: 14.

8. The use of any one of claims 1-7, wherein the IL-4R inhibitor is dupilumab or a bioequivalent thereof.

9. The use of any one of claims 1-8, wherein the pharmaceutical composition or medicament is formulated to be subcutaneously administered.

10. The use of any one of claims 1-9, wherein each dose of the pharmaceutical composition or medicament comprises 50 – 600 mg of the antibody or antigen-binding fragment thereof.

11. The use of claim 10, wherein each dose comprises 300 mg of the antibody or antigen-binding fragment thereof.

12. The use of any one of claims 1-11, wherein the pharmaceutical composition or medicament is formulated to be administered once a week, once every two weeks, once every three weeks, or once a month.

13. The use of any one of claims 1-12, wherein the pharmaceutical composition or medicament is formulated to be administered at a dose of 300 mg of the antibody or antigen-binding fragment thereof once a week or once every two weeks.

14. The use of any one of claims 1-10, wherein the pharmaceutical composition or medicament is formulated to be administered at an initial dose followed by one or more subsequent doses, wherein each subsequent dose is administered to the subject one week or two weeks after the immediately preceding dose.

15. The use of claim 14, wherein the initial dose comprises 600 mg of the antibody or antigen-binding fragment thereof and each subsequent dose comprises 300 mg of the antibody or antigen-binding fragment thereof.

16. The use of claim 15, wherein:

each subsequent dose is administered to the subject one week after the immediately preceding dose; or

each subsequent dose is administered to the subject two weeks after the immediately preceding dose.

17. The use of any one of claims 1-16, wherein the pharmaceutical composition or medicament is contained in a syringe.

18. The use of any one of claims 1-16, wherein the pharmaceutical composition or medicament is contained in a pen delivery device.

19. The use of claim 18, wherein:

the pen delivery device is a reusable pen delivery device comprising a replaceable cartridge comprising the pharmaceutical composition or medicament; or

the pen delivery device is a disposable pen delivery device that is prefilled with the pharmaceutical composition or medicament.